{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:03:14Z","timestamp":1775840594053,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.intimp.2023.109693","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T19:59:15Z","timestamp":1673467155000},"page":"109693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17\/Treg cells via regulating the JAK2\/STAT3-AKT\/mTOR signaling pathway"],"prefix":"10.1016","volume":"115","author":[{"given":"Yaru","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1909-4898","authenticated-orcid":false,"given":"Weibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.intimp.2023.109693_b0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109693_b0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"Gilhus","year":"2019","journal-title":"Myasthenia gravis. Nat Rev Dis Primers."},{"issue":"1","key":"10.1016\/j.intimp.2023.109693_b0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.intimp.2023.109693_b0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.molimm.2022.08.018","article-title":"Complement and myasthenia gravis","volume":"151","author":"Sanderson","year":"2022","journal-title":"Mol Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2023.109693_b0025","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.autrev.2013.03.003","article-title":"Complement associated pathogenic mechanisms in myasthenia gravis","volume":"12","author":"T\u00fcz\u00fcn","year":"2013","journal-title":"Autoimmun Rev."},{"issue":"2","key":"10.1016\/j.intimp.2023.109693_b0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Autoimmun."},{"key":"10.1016\/j.intimp.2023.109693_b0035","doi-asserted-by":"crossref","unstructured":"Burkett PR, Meyer zu Horste G and Kuchroo VK. Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J Clin Invest. 2015;125(6):2211-9. doi: 10.1172\/JCI78085.","DOI":"10.1172\/JCI78085"},{"key":"10.1016\/j.intimp.2023.109693_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108492","article-title":"Circulating Th1\/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients","volume":"218","author":"Ma","year":"2020","journal-title":"Clin Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109693_b0045","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/cells9071611","article-title":"Identification of Novel Molecular Markers of Human Th17 Cells","volume":"9","author":"Sa\u0142kowska","year":"2020","journal-title":"Cells."},{"issue":"4","key":"10.1016\/j.intimp.2023.109693_b0050","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.immuni.2020.03.013","article-title":"Insulin-Like Growth Factors Are Key Regulators of T Helper 17 Regulatory T Cell Balance in Autoimmunity","volume":"52","author":"DiToro","year":"2020","journal-title":"Immunity."},{"key":"10.1016\/j.intimp.2023.109693_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2020.08.002","article-title":"Decipher manifestations and Treg \/Th17 imbalance in multi-staging rheumatoid arthritis and correlation with TSDR\/RORC methylation","volume":"127","author":"Huang","year":"2020","journal-title":"Mol Immunol."},{"key":"10.1016\/j.intimp.2023.109693_b0060","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3389\/fimmu.2020.01027","article-title":"T Cell Metabolism: A New Perspective on Th17\/Treg Cell Imbalance in Systemic Lupus Erythematosus","volume":"11","author":"Shan","year":"2020","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109693_b0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00441-020-03359-7","article-title":"The role of Treg subtypes in glomerulonephritis","volume":"385","author":"Herrnstadt","year":"2021","journal-title":"Cell Tissue Res."},{"issue":"9","key":"10.1016\/j.intimp.2023.109693_b0070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nri.2017.50","article-title":"The dichotomous nature of T helper 17 cells","volume":"17","author":"Stockinger","year":"2017","journal-title":"Nat Rev Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2023.109693_b0075","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109693_b0080","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109693_b0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.immuni.2015.11.009","article-title":"Interleukin-23-Induced Transcription Factor Blimp-1 Promotes Pathogenicity of T Helper 17 Cells","volume":"44","author":"Jain","year":"2016","journal-title":"Immunity."},{"key":"10.1016\/j.intimp.2023.109693_b0090","article-title":"The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa","volume":"23(7):13030\/qt8rw2j9zv","author":"Yao","year":"2017","journal-title":"Dermatol Online J."},{"key":"10.1016\/j.intimp.2023.109693_b0095","article-title":"The Yin and Yang of IL-17 in Systemic Sclerosis","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109693_b0100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.1993","article-title":"Fate mapping of IL-17-producing T cells in inflammatory responses","volume":"12","author":"Hirota","year":"2011","journal-title":"Nat Immunol."},{"issue":"7318","key":"10.1016\/j.intimp.2023.109693_b0105","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","article-title":"Generation of pathogenic T(H)17 cells in the absence of TGF-\u03b2 signalling","volume":"467","author":"Ghoreschi","year":"2010","journal-title":"Nature."},{"issue":"4","key":"10.1016\/j.intimp.2023.109693_b0110","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 Family of Cytokines in Health and Disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity."},{"issue":"3","key":"10.1016\/j.intimp.2023.109693_b0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/03009742.2014.962080","article-title":"Interleukin-27 and interleukin-23 in patients with systemic lupus erythematosus: possible role in lupus nephritis","volume":"44","author":"Xia","year":"2015","journal-title":"Scand J Rheumatol."},{"issue":"11","key":"10.1016\/j.intimp.2023.109693_b0120","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/jir.2020.0113","article-title":"Evaluation of Interleukin-23 and JAKs\/STATs\/SOCSs\/ROR-\u03b3t Expression in Type 2 Diabetes Mellitus Patients Treated With or Without Sitagliptin","volume":"40","author":"Rezaeepoor","year":"2020","journal-title":"J Interferon Cytokine Res."},{"key":"10.1016\/j.intimp.2023.109693_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109693_b0130","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.21037\/tp-21-39","article-title":"Effect of SOCS3 on apoptosis of human trophoblasts via adjustment of the JAK2\/STAT3 signaling pathway in preterm birth","volume":"10","author":"Yin","year":"2021","journal-title":"Transl Pediatr."},{"key":"10.1016\/j.intimp.2023.109693_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112155","article-title":"Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders","volume":"192","author":"Xu","year":"2020","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.intimp.2023.109693_b0140","article-title":"Pathogenic and Therapeutic Relevance of JAK\/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent","volume":"8(8):898","author":"Alunno","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.intimp.2023.109693_b0145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/nyas.12059","article-title":"Role of PI3K\/Akt and mTOR complexes in Th17 cell differentiation","volume":"1280","author":"Nagai","year":"2013","journal-title":"Ann N Y Acad Sci."},{"issue":"6","key":"10.1016\/j.intimp.2023.109693_b0150","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2009.04.014","article-title":"The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment","volume":"30","author":"Delgoffe","year":"2009","journal-title":"Immunity."},{"key":"10.1016\/j.intimp.2023.109693_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2020.111177","article-title":"The imbalance of Treg\/Th17 cells induced by perinatal bisphenol A exposure is associated with activation of the PI3K\/Akt\/mTOR signaling pathway in male offspring mice","volume":"137","author":"Gao","year":"2020","journal-title":"Food Chem Toxicol."},{"key":"10.1016\/j.intimp.2023.109693_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107434","article-title":"Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses","volume":"93","author":"Huang","year":"2021","journal-title":"Int Immunopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109693_b0165","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.sjbs.2016.08.015","article-title":"Immune characteristics study of AG490, a signal pathway inhibitor, in EAE model mice","volume":"24","author":"Zhao","year":"2017","journal-title":"Saudi J Biol Sci."},{"issue":"9","key":"10.1016\/j.intimp.2023.109693_b0170","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.4049\/jimmunol.1300514","article-title":"JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T Cells and Th17 cells","volume":"192","author":"Park","year":"2014","journal-title":"J Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109693_b0175","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/1440-1681.13311","article-title":"The JAK2 inhibitor AG490 regulates the Treg\/Th17 balance and alleviates DSS-induced intestinal damage in IBD rats","volume":"47","author":"Guo","year":"2020","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"10.1016\/j.intimp.2023.109693_b0180","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.biopha.2016.02.015","article-title":"Protective mechanisms of berberine against experimental autoimmune myocarditis in a rat model","volume":"79","author":"Liu","year":"2016","journal-title":"Biomed Pharmacother."},{"issue":"10","key":"10.1016\/j.intimp.2023.109693_b0185","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0961203310367660","article-title":"Jak\/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL\/lpr mice","volume":"19","author":"Wang","year":"2010","journal-title":"Lupus."},{"key":"10.1016\/j.intimp.2023.109693_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.820664","article-title":"Red Nucleus Interleukin-6 Evokes Tactile Allodynia in Male Rats Through Modulating Spinal Pro-inflammatory and Anti-inflammatory Cytokines","volume":"15","author":"Yang","year":"2022","journal-title":"Front Mol Neurosci."},{"issue":"11","key":"10.1016\/j.intimp.2023.109693_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev."},{"issue":"12","key":"10.1016\/j.intimp.2023.109693_b0205","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem."},{"issue":"1","key":"10.1016\/j.intimp.2023.109693_b0210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"10.1016\/j.intimp.2023.109693_b0215","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109693_b0220","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109693_b0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.it.2014.10.006","article-title":"Intersection of mTOR and STAT signaling in immunity","volume":"36","author":"Saleiro","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2023.109693_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684197","article-title":"Mesenchymal Stem Cell Protects Injured Renal Tubular Epithelial Cells by Regulating mTOR-Mediated Th17\/Treg Axis","volume":"12","author":"Luo","year":"2021","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109693_b0235","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.20110278","article-title":"HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells","volume":"208","author":"Shi","year":"2011","journal-title":"J Exp Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.109693_b0240","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/ni.1698","article-title":"The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat Immunol."},{"key":"10.1016\/j.intimp.2023.109693_b0245","article-title":"Rapamycin alleviates inflammation and muscle weakness, while altering the Treg\/Th17 balance in a rat model of myasthenia gravis","volume":"37(4):BSR20170767","author":"Jing","year":"2017","journal-title":"Biosci Rep."},{"issue":"6","key":"10.1016\/j.intimp.2023.109693_b0250","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology."},{"issue":"1","key":"10.1016\/j.intimp.2023.109693_b0255","doi-asserted-by":"crossref","first-page":"e54826","DOI":"10.1371\/journal.pone.0054826","article-title":"mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms","volume":"8","author":"Bogani","year":"2013","journal-title":"PLoS One."},{"issue":"6","key":"10.1016\/j.intimp.2023.109693_b0260","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nri2093","article-title":"SOCS proteins, cytokine signalling and immune regulation","volume":"7","author":"Yoshimura","year":"2007","journal-title":"Nat Rev Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109693_b0265","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cytogfr.2013.03.005","article-title":"Suppression of cytokine signaling: the SOCS perspective","volume":"24","author":"Linossi","year":"2013","journal-title":"Cytokine Growth Factor Rev."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923000164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923000164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:10:01Z","timestamp":1736431801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923000164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":52,"alternative-id":["S1567576923000164"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109693","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17\/Treg cells via regulating the JAK2\/STAT3-AKT\/mTOR signaling pathway","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109693"}}